Retatrutide for osteoarthritis, knee

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jul 2023: Trial registered, NCT05929066
  2. 10 Jul 2023: Trial started, NCT05929066

The trials

NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

State
Completed
Phase
Phase 3
People
2,335 taking part
Started
10 Jul 2023
Primary completion
6 Apr 2026
Arms
Retatrutide Dose 1, Retatrutide Dose 2, Retatrutide Dose 3, Retatrutide Extension Period
Results
None posted
  1. 3 Jul 2023: Trial registered
  2. 10 Jul 2023: Trial started
  3. 30 Apr 2026: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Retatrutide (LY3437943).

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.